Pooled data from ASPIRE I and II indicate that esketamine nasal spray plus standard of care produced greater patient‑reported improvements in health‑related quality of life and treatment satisfaction than placebo plus standard of care in adults with major depressive disorder and active suicidal ideation. The benefit was statistically significant on the QLDS (LS mean difference −3.1, 95% CI −5.21 to −1.02), with non‑significant change on the Beck Hopelessness Scale and favourable trends on EQ‑5D‑5L indices and TSQM‑9 domains.
- Published
- Journal
- Quality of Life Research
- Authors
- Jamieson, C., Canuso, C. M., Ionescu, D. F., Lane, R., Qiu, X., Rozjabek, H., Molero, P., Fu, D. J.